bepridil has been researched along with Diabetes Mellitus, Type 2 in 1 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Husted, SE | 1 |
| Pedersen, C | 1 |
| Nielsen, HK | 1 |
| Apoil, E | 1 |
| Nielsen, OH | 1 |
| Lindvig, K | 1 |
| Krusell, LR | 1 |
| Høegholm, A | 1 |
1 trial available for bepridil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of bepridil on metabolic control and insulin secretion in diabetics.
Topics: Adult; Bepridil; Blood Glucose; Calcium Channel Blockers; Cholesterol; Clinical Trials as Topic; Dia | 1988 |